Sensei Biotherapeutics Inc (SNSE) is a Healthcare · Biotechnology company listed on NASDAQ. Price $35.13 (+2.60%), Market cap $0.02B, 52-week low–high $0.29 ~ $35.07.
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known a
Financial statements, price targets, institutional (13F) holdings and related news for Sensei Biotherapeutics Inc are updated in real time on BlackAll Trade.
Sensei Biotherapeutics Inc trades at $35.13 (+2.60%). Real-time quotes and charts are available on BlackAll Trade.
Sensei Biotherapeutics Inc has a market cap of about $0.02B.
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-